江苏吴中(600200) - 2019 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders decreased by 314.41% to CNY -56,098,229.25 for the period from January to September[17] - Basic earnings per share decreased by 51.88% to CNY 0.077 compared to the same period last year[17] - Operating cash flow decreased by 58.19% to CNY 73,175,030.81 for the period from January to September[17] - Total operating revenue for the first three quarters of 2019 reached ¥1,517,839,873.94, an increase from ¥1,398,239,798.67 in the same period of 2018, representing a growth of approximately 8.6%[57] - Net profit for the third quarter of 2019 was ¥2,402,150.79, a decrease from ¥30,521,092.78 in the same quarter of 2018[60] - Net profit for Q3 2019 was approximately -¥14.76 million, compared to a profit of ¥31.32 million in Q3 2018, indicating a significant decline[72] - Total comprehensive income for Q3 2019 was approximately -¥14.76 million, compared to -¥6.75 million in Q3 2018[75] Assets and Liabilities - Total assets decreased by 13.5% to CNY 3,994,675,605.72 compared to the end of the previous year[17] - Total current assets decreased from 2,708,751,693.00 to 2,099,655,847.40, a decline of approximately 22.5%[41] - Total liabilities decreased from 2,209,800,353.31 to 1,595,827,263.37, a reduction of approximately 27.7%[47] - Total non-current assets slightly decreased from 1,909,159,208.74 to 1,895,019,758.32, a decline of about 0.7%[43] - Total liabilities reached $728.20 million, with current liabilities totaling $641.20 million[97] Cash Flow - Net cash flow from operating activities decreased by 58.19% to ¥7,317.50 million due to reduced tax refunds[29] - The net cash flow from operating activities for the first nine months of 2019 was -344,912,113.73 RMB, compared to -275,303,673.56 RMB in the same period of 2018, indicating a decline in operational cash flow[81] - Cash outflow for operating activities was 555,900,740.30 RMB, slightly up from 530,098,730.48 RMB in the previous year, reflecting increased operational costs[81] - The ending balance of cash and cash equivalents was 45,723,535.05 RMB, down from 124,223,945.20 RMB at the end of the previous year, showing a reduction in liquidity[83] Shareholder Information - The largest shareholder, Suzhou Wuzhong Investment Holding Co., Ltd., holds 17.24% of the shares[20] - The company reported a total of 73,270 shareholders at the end of the reporting period[20] Research and Development - The company received government subsidies of CNY 11,672,862.46 related to new drug research and development during the period from January to September[19] - Research and development expenses for the third quarter of 2019 were ¥1,572,679.77, down from ¥5,890,521.12 in the same quarter of 2018, showing a decrease of about 73%[57] - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[90] Other Financial Metrics - Financial expenses rose by 54.26% to ¥3,610.48 million as average borrowings increased[29] - The company reported an investment income of ¥130,520,178.88 for the third quarter of 2019, compared to ¥59,737,244.44 in the same quarter of 2018, representing an increase of approximately 118%[57] - The company received 100,000,000.00 RMB in investment income, a significant increase from 5,953,389.66 RMB in the same period last year, indicating improved investment performance[81] Equity and Ownership - Total owner's equity slightly decreased from 2,408,110,548.43 to 2,398,848,342.35, a reduction of about 0.5%[47] - Shareholders' equity totaled $2.10 billion, including an undistributed profit of -$203.12 million[99] - The company reported a capital reserve of approximately $1.46 billion[97]